Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study a randomized clinical trial

Medicine and Dentistry

• Injection 100%
• Aflibercept 100%
• Photodynamic Therapy 54%
• Monotherapy 36%
• Randomized Clinical Trial 18%
• Polypoidal Choroidal Vasculopathy 18%
• Lesion 13%
• Woman 9%
• Therapeutic Procedure 9%
• Best Corrected Visual Acuity 9%
• Age 4%
• Adverse Event 4%
• Diabetic Retinopathy 4%
• Group Therapy 4%
• Dry Eye 4%
• Indocyanine Green Angiography 4%
• Rescue Therapy 4%

Nursing and Health Professions

• Injection 100%
• Aflibercept 100%
• Photodynamic Therapy 54%
• Monotherapy 36%
• Emergency Medical Technician 27%
• Polypoidal Choroidal Vasculopathy 18%
• Best Corrected Visual Acuity 9%
• Adult 9%
• Adverse Event 4%
• Electric Potential 4%
• Thickness 4%
• Group Therapy 4%
• Dry Eye 4%
• Diabetic Retinopathy 4%
• Rescue Therapy 4%
• Indocyanine Green Angiography 4%
• Conjunctival Hemorrhage 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Aflibercept 100%
• Monotherapy 36%
• Polypoidal Choroidal Vasculopathy 18%
• Adverse Event 4%
• Diabetic Retinopathy 4%
• Dry Eye 4%
• Conjunctival Hemorrhage 4%